



## BELLUS Health to Present at Jefferies Global Healthcare Conference in London

November 13, 2019

LAVAL, Quebec--(BUSINESS WIRE)--Nov. 13, 2019-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company on Wednesday, November 20, 2019 at the Jefferies Global Healthcare Conference in London.

### Presentation Details:

**Event:** Jefferies Global Healthcare Conference in London

**Date/Time:** Wednesday, November 20, 2019 at 9:20 a.m. GMT

**Location:** London

A live webcast may be accessed on the [Events and Presentations](#) page under the Investors & News section of BELLUS Health's website at [www.bellushealth.com](http://www.bellushealth.com). Following the event, an archived webcast and presentation will be available on the Company's website.

### About BELLUS Health

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191113005189/en/>

Source: BELLUS Health Inc.

#### Investors:

François Desjardins

Vice President, Finance

450-680-4525

[fdesjardins@bellushealth.com](mailto:fdesjardins@bellushealth.com)

Solebury Trout

Chad Rubin

646-378-2947

[crubin@troutgroup.com](mailto:crubin@troutgroup.com)

#### Media:

Solebury Trout

Joshua R. Mansbach

646-378-2964

[jmansbach@troutgroup.com](mailto:jmansbach@troutgroup.com)